Cite This Page

Jump to: navigation, search

Bibliographic details for Improved Side upon MDCT regarding Intestinal tract Liver Metastases Assessment associated with Ability to Predict ProgressionFree Survival and Reply to BevacizumabBased Radiation

Citation styles for Improved Side upon MDCT regarding Intestinal tract Liver Metastases Assessment associated with Ability to Predict ProgressionFree Survival and Reply to BevacizumabBased Radiation

APA style

Improved Side upon MDCT regarding Intestinal tract Liver Metastases Assessment associated with Ability to Predict ProgressionFree Survival and Reply to BevacizumabBased Radiation. (2024, January 18). OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . Retrieved 12:10, June 12, 2024 from https://news.npo.digital/index.php?title=Improved_Side_upon_MDCT_regarding_Intestinal_tract_Liver_Metastases_Assessment_associated_with_Ability_to_Predict_ProgressionFree_Survival_and_Reply_to_BevacizumabBased_Radiation&oldid=564323.

MLA style

"Improved Side upon MDCT regarding Intestinal tract Liver Metastases Assessment associated with Ability to Predict ProgressionFree Survival and Reply to BevacizumabBased Radiation." OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . 18 Jan 2024, 15:57 UTC. 12 Jun 2024, 12:10 <https://news.npo.digital/index.php?title=Improved_Side_upon_MDCT_regarding_Intestinal_tract_Liver_Metastases_Assessment_associated_with_Ability_to_Predict_ProgressionFree_Survival_and_Reply_to_BevacizumabBased_Radiation&oldid=564323>.

MHRA style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, 'Improved Side upon MDCT regarding Intestinal tract Liver Metastases Assessment associated with Ability to Predict ProgressionFree Survival and Reply to BevacizumabBased Radiation', OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , 18 January 2024, 15:57 UTC, <https://news.npo.digital/index.php?title=Improved_Side_upon_MDCT_regarding_Intestinal_tract_Liver_Metastases_Assessment_associated_with_Ability_to_Predict_ProgressionFree_Survival_and_Reply_to_BevacizumabBased_Radiation&oldid=564323> [accessed 12 June 2024]

Chicago style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, "Improved Side upon MDCT regarding Intestinal tract Liver Metastases Assessment associated with Ability to Predict ProgressionFree Survival and Reply to BevacizumabBased Radiation," OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , https://news.npo.digital/index.php?title=Improved_Side_upon_MDCT_regarding_Intestinal_tract_Liver_Metastases_Assessment_associated_with_Ability_to_Predict_ProgressionFree_Survival_and_Reply_to_BevacizumabBased_Radiation&oldid=564323 (accessed June 12, 2024).

CBE/CSE style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors. Improved Side upon MDCT regarding Intestinal tract Liver Metastases Assessment associated with Ability to Predict ProgressionFree Survival and Reply to BevacizumabBased Radiation [Internet]. OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, ; 2024 Jan 18, 15:57 UTC [cited 2024 Jun 12]. Available from: https://news.npo.digital/index.php?title=Improved_Side_upon_MDCT_regarding_Intestinal_tract_Liver_Metastases_Assessment_associated_with_Ability_to_Predict_ProgressionFree_Survival_and_Reply_to_BevacizumabBased_Radiation&oldid=564323.

Bluebook style

Improved Side upon MDCT regarding Intestinal tract Liver Metastases Assessment associated with Ability to Predict ProgressionFree Survival and Reply to BevacizumabBased Radiation, https://news.npo.digital/index.php?title=Improved_Side_upon_MDCT_regarding_Intestinal_tract_Liver_Metastases_Assessment_associated_with_Ability_to_Predict_ProgressionFree_Survival_and_Reply_to_BevacizumabBased_Radiation&oldid=564323 (last visited June 12, 2024).

BibTeX entry

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "Improved Side upon MDCT regarding Intestinal tract Liver Metastases Assessment associated with Ability to Predict ProgressionFree Survival and Reply to BevacizumabBased Radiation --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "https://news.npo.digital/index.php?title=Improved_Side_upon_MDCT_regarding_Intestinal_tract_Liver_Metastases_Assessment_associated_with_Ability_to_Predict_ProgressionFree_Survival_and_Reply_to_BevacizumabBased_Radiation&oldid=564323",
   note = "[Online; accessed 12-June-2024]"
 }

When using the LaTeX package url (\usepackage{url} somewhere in the preamble) which tends to give much more nicely formatted web addresses, the following may be preferred: 

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "Improved Side upon MDCT regarding Intestinal tract Liver Metastases Assessment associated with Ability to Predict ProgressionFree Survival and Reply to BevacizumabBased Radiation --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "\url{https://news.npo.digital/index.php?title=Improved_Side_upon_MDCT_regarding_Intestinal_tract_Liver_Metastases_Assessment_associated_with_Ability_to_Predict_ProgressionFree_Survival_and_Reply_to_BevacizumabBased_Radiation&oldid=564323}",
   note = "[Online; accessed 12-June-2024]"
 }


Retrieved from "https://news.npo.digital/index.php?title=Special:CiteThisPage"